about
Advances in the treatment of relapsed or refractory Hodgkin's lymphomaDetermination of hypersensitivity to genotoxic agents among Escherichia coli single gene knockout mutantsBrentuximab vedotin for relapsed or refractory CD30+ Hodgkin lymphoma: a multicenter analysis from Asia.Neutropenia and Neutropenic Complications in ABVD Chemotherapy for Hodgkin LymphomaThree-dimensional Telomere Signatures of Hodgkin- and Reed-Sternberg Cells at Diagnosis Identify Patients with Poor Response to Conventional ChemotherapyPhase II Study of the Efficacy and Safety of Pembrolizumab for Relapsed/Refractory Classic Hodgkin Lymphoma.The European Medicines Agency Review of Brentuximab Vedotin (Adcetris) for the Treatment of Adult Patients With Relapsed or Refractory CD30+ Hodgkin Lymphoma or Systemic Anaplastic Large Cell Lymphoma: Summary of the Scientific Assessment of the ComSerial diffusion MRI to monitor and model treatment response of the targeted nanotherapy CRLX101Brentuximab vedotin treatment for primary refractory hodgkin lymphoma.Prognostic Factors and a New Prognostic Index Model for Children and Adolescents with Hodgkin's Lymphoma Who Underwent Autologous Hematopoietic Stem Cell Transplantation: A Multicenter Study of the Turkish Pediatric Bone Marrow Transplantation StudyCD30: an important new target in hematologic malignancies.Double high-dose therapy with dose-intensive cyclophosphamide, etoposide, cisplatin (DICEP) followed by high-dose melphalan and autologous stem cell transplantation for relapsed/refractory Hodgkin lymphoma.Hematopoietic progenitor cells transplantation for recurrent or refractory Hodgkin's lymphoma.Therapeutic effects of thalidomide in hematologic disorders: a review.Improving Outcome of Hodgkins Disease with Autologous Hematopoietic Stem Cell Transplantation.Economic impact of disease progression following front-line therapy in classical Hodgkin lymphoma.Detection of classical Hodgkin lymphoma specific sequence in peripheral blood using a next-generation sequencing approach.Dynamic chromosomal rearrangements in Hodgkin's lymphoma are due to ongoing three-dimensional nuclear remodeling and breakage-bridge-fusion cyclesThe role of hematopoietic stem cell transplantation for relapsed and refractory Hodgkin lymphoma.Brentuximab vedotin with AVD shows safety, in the absence of strong CYP3A4 inhibitors, in newly diagnosed HIV-associated Hodgkin lymphoma.QS-ZYX-1-61 induces apoptosis through topoisomerase II in human non-small-cell lung cancer A549 cells.Clinical features and outcomes of Hodgkin's lymphoma in Korea: Consortium for Improving Survival of Lymphoma (CISL)Real-world analysis of cost, health care resource utilization, and supportive care in Hodgkin lymphoma patients with frontline failure
P2860
Q27694504-4D8643D8-E776-4B1A-A4BB-FA11EE9AFD7AQ34088322-E9F286D8-5730-4962-BAF1-1DA6BB793F72Q34337660-004B20C4-B284-46AA-9F21-223B09C3875CQ35038832-B1D4AF89-0A19-49D6-AF64-33831458FEEFQ36199852-E64B7F5F-702C-4237-A8C7-BFF80C88267DQ36356089-C48B1E73-BAC6-4CDC-9AAF-A8F27F4EF074Q36452273-2652ACBD-539D-44FE-A852-04CBE7C32321Q36815253-88EC7AC3-3528-44E9-A783-9C779D00D3EBQ37254777-3F63D817-A417-4B24-A3AF-E8C7B8BF0D77Q37548240-7FC7063F-CEEC-4051-B176-F505876BFE0AQ37880873-5803B443-4C8D-4D8A-A238-7142E037C2AAQ37934952-1ABF8536-10F9-4A34-B631-E9DDF1AD7E51Q38099028-A4292A4A-7054-4013-AD19-89F44CD748F2Q38121762-EE52C064-F005-4A4C-A567-15E7514F4188Q38955399-F44EF2E4-3411-481A-B77F-EE78EF85C2A1Q39019556-433CF8A7-C46D-4F87-B817-4DA1E338F8FDQ39024241-298F24EC-416F-4F93-A3BE-F40A2BDBEE89Q39658596-217FB5E2-5C2B-49B0-B409-68E6692DF319Q43716206-B65B54F4-A1EE-46FD-B7B2-EB0A65855574Q48528597-7EF9C9AC-B3C8-42CA-BA57-B12663B073D9Q53219322-C91BD0A5-820E-4503-98DD-B27D4CD64A24Q57225717-5F769DBB-57BC-4AF8-AEFD-E6FC6CA0C750Q58605819-010EE3F2-45D4-43CA-8BA3-933EAF33DFE9
P2860
description
2009 nî lūn-bûn
@nan
2009 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
Standard therapy of advanced Hodgkin lymphoma
@ast
Standard therapy of advanced Hodgkin lymphoma
@en
Standard therapy of advanced Hodgkin lymphoma
@en-gb
Standard therapy of advanced Hodgkin lymphoma
@nl
type
label
Standard therapy of advanced Hodgkin lymphoma
@ast
Standard therapy of advanced Hodgkin lymphoma
@en
Standard therapy of advanced Hodgkin lymphoma
@en-gb
Standard therapy of advanced Hodgkin lymphoma
@nl
prefLabel
Standard therapy of advanced Hodgkin lymphoma
@ast
Standard therapy of advanced Hodgkin lymphoma
@en
Standard therapy of advanced Hodgkin lymphoma
@en-gb
Standard therapy of advanced Hodgkin lymphoma
@nl
P3181
P1476
Standard therapy of advanced Hodgkin lymphoma
@en
P2093
J. Kuruvilla
P304
P3181
P356
10.1182/ASHEDUCATION-2009.1.497
P407
P577
2009-01-01T00:00:00Z